Logo Prima Biomed

Pipeline

Please click on the appropriate product for detailed information.



Please click on the picture to display the pipeline as pdf.

 

 

Save

Save

Save

Save

Save

Save

Save

Save

LAG-3 Technologies

IMP321 (soluble LAG-3Ig)

Preclinical Phase I Phase IIa Phase IIb

Metastatic

Breast Cancer

 WW Prima

(ex China: Eddingpharm)
Phase IIb trial began Oct 2015
MOA: APC activator following first-line chemotherapy leading to immunostimulation

Proof of Concept
Study in Metastatic
Melanoma

 WW Prima

(ex China: Eddingpharm)
Phase I trial began Jan 2016
MOA: APC activator + PD-1 checkpoint inhibitor (i.e. KEYTRUDA) leading to immunostimulation

IMP731 (depleting LAG-3 mAb)

Autoimmune

Diseases

 WW GSK

Phase I trial began Jan 2015
MOA: LAG-3 depleting antibody leading to immunosuppression

IMP701 (antagonist LAG-3 mAb)

Cancer

 WW Novartis

Phase I trial began Aug 2015
MOA: LAG-3 antagonist antibody leading to immunostimulation

IMP761 (agonist LAG-3 mAb)

Autoimmune

Diseases

 WW Prima

MOA: LAG-3 agonist antibody leading to immunosuppression


Autologous Dendritic Cell Therapy

CVac™

Ovarian Cancer

 WW Sydys Corporation

(ex Israel: Neopharm)
Phase IIb completed (CAN-003)